Brief: Y-Mabs Reports First Quarter 2023 Financial Results

Y-mAbs Therapeutics

08/05/2023 23:17

May 8 (Reuters) - Y-Mabs Therapeutics Inc  YMAB.O :
    * Y-MABS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND
RECENT
CORPORATE DEVELOPMENTS AND UPDATES 2023 FINANCIAL GUIDANCE
    * CASH AND CASH EQUIVALENTS OF $92.6 MILLION AS OF MARCH 31,
2023,
ANTICIPATED CASH RUNWAY INTO Q1 2026
    * Y-MABS THERAPEUTICS - UPDATES 2023 FINANCIAL GUIDANCE,
ANTICIPATING HIGHER DANYELZA NET REVENUE OF $80-85 MILLION &
LOWER CASH BURN OF $40-50 MILLION FOR FY 2023
    * Q1 2023 DANYELZA RECORD NET PRODUCT REVENUES OF $20.3
MILLION
    * QTRLY LOSS PER SHARE $0.15
    * Q1 EARNINGS PER SHARE VIEW $-0.32, REVENUE VIEW $15.6
MILLION --
REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX59Fz1d 
Further company coverage:  YMAB.O 

 ((Reutersbriefs@thomsonreuters.com;))